{
  "docId": "019de074-abc1-773c-9c2f-d49993e7b79a",
  "docSlug": "59a1ae16b5e60c748be3b046cd750424",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 20 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4138439,
  "pageNumber": 6,
  "pageCount": 20,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes Kaplan-Meier EFS curve and pCR bar chart with associated statistical table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-abc1-773c-9c2f-d49993e7b79a/6",
  "deckHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a",
  "deckJsonHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a.json",
  "deckAnchorHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.72,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Final analysis of pathologic complete response (pCR)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d743597-fd7d-4041-8db3-6e9f0141673a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.32,
        "y": 0.2
      },
      "kind": "chart",
      "text": "First planned interim analysis of event-free survival (EFS)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8808741-7305-43cd-a31b-c1375ff36893",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "While metastatic disease has long been an area of focus in cancer research, we have been continuously looking for opportunities to treat cancer in earlier stages in which there is the greatest potential for cure.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59627b32-bf77-4edd-bc7f-48beaf6ad69f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.72,
        "y": 0.65
      },
      "kind": "source-note",
      "text": "Heymach, JV. CT005 - AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. AACR 2023. Abstract #CT005.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96dde6bd-0653-46fb-825c-c128307dbed9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.65,
        "x": 0.32,
        "y": 0.7
      },
      "kind": "table",
      "text": "EFS and pCR statistical summary table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e2d41fd-379f-4f70-951a-a5f8f2313d60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "New at #AACR23: Novel Imfinzi-based regimen significantly improved patient outcomes in resectable non-small cell lung cancer in AEGEAN Phase III trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05456e0a-f07c-4561-b6a1-885030909147",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 3,
      "beatId": "ed5d30db-7be1-4ae3-b0d2-434376fe7c11",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "Key messages and thesis headline generate interest in AstraZeneca's oncology ambition.",
      "position": 1,
      "confidence": 0.7,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}